Form 8-K - Current report:
SEC Accession No. 0001683168-24-006318
Filing Date
2024-09-12
Accepted
2024-09-12 08:58:31
Documents
13
Period of Report
2024-09-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 28700
  Complete submission text file 0001683168-24-006318.txt   204247

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cnsp-20240910.xsd EX-101.SCH 3018
3 XBRL LABEL FILE cnsp-20240910_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE cnsp-20240910_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3802
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 241294002
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)